|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q42591886
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000309.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q42591886
|
|
024
|
|
|
‡a
0000-0003-2000-2874
‡2
orcid
|
|
024
|
|
|
‡a
55544802200
‡2
scopus
|
|
024
|
|
|
‡a
7403298476
‡2
scopus
|
|
024
|
|
|
‡a
57019514500
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q42591886
|
|
100
|
0 |
|
‡a
Richard Price
‡9
eo
‡9
co
‡9
io
‡9
af
‡9
vi
‡9
is
‡9
it
‡9
an
‡9
eu
‡9
cy
‡9
gd
‡9
pt-br
‡9
ga
‡9
zu
‡9
cs
‡9
et
‡9
gl
‡9
ie
‡9
id
‡9
es
‡9
en-gb
‡9
lb
‡9
wa
‡9
nn
‡9
min
‡9
nys
‡9
nb
‡9
pms
‡9
tr
‡9
lij
‡9
li
‡9
wo
‡9
nap
‡9
frp
‡9
nds-nl
‡9
fi
‡9
rm
‡9
en-ca
‡9
ia
‡9
ca
‡9
pcd
‡9
vec
‡9
sco
‡9
nrm
‡9
ast
‡9
hr
‡9
de
‡9
hu
‡9
da
‡9
fr
‡9
sc
‡9
oc
‡9
br
‡9
vls
‡9
vo
‡9
kg
‡9
fo
‡9
scn
‡9
mg
‡9
ro
‡9
bar
‡9
pt
‡9
gsw
‡9
fur
‡9
sq
‡9
sw
‡9
sv
‡9
de-ch
‡9
kl
‡9
sk
‡9
sr-el
‡9
pl
‡9
ms
‡9
sl
‡9
de-at
‡9
nds
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
রিচার্ড প্রাইস
‡9
bn
|
|
400
|
0 |
|
‡a
Richard Price
‡c
professor of tropical medicine and physician
‡9
en
|
|
400
|
0 |
|
‡a
Richard Price
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's 3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity
|
|
670
|
|
|
‡a
Author's A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria.
|
|
670
|
|
|
‡a
Author's A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh
|
|
670
|
|
|
‡a
Author's A long neglected world malaria map: Plasmodium vivax endemicity in 2010
|
|
670
|
|
|
‡a
Author's A model for malaria treatment evaluation in the presence of multiple species
|
|
670
|
|
|
‡a
Author's A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes
|
|
670
|
|
|
‡a
Author's A novel multiple-stage antimalarial agent that inhibits protein synthesis
|
|
670
|
|
|
‡a
Author's A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics
|
|
670
|
|
|
‡a
Author's A simple score to predict the outcome of severe malaria in adults
|
|
670
|
|
|
‡a
Author's A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults
|
|
670
|
|
|
‡a
Author's A systematic review of published antimalarial clinical trials: parasite clearance of artemisinin-containing regimens in the treatment of uncomplicated malaria
|
|
670
|
|
|
‡a
Author's A systematic review of sub-microscopic Plasmodium vivax infection
|
|
670
|
|
|
‡a
Author's A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
|
|
670
|
|
|
‡a
Author's A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor
|
|
670
|
|
|
‡a
Author's A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria
|
|
670
|
|
|
‡a
Author's Advances in Parasitology. Preface
|
|
670
|
|
|
‡a
Author's Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients
|
|
670
|
|
|
‡a
Author's Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic
|
|
670
|
|
|
‡a
Author's Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans
|
|
670
|
|
|
‡a
Author's Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax
|
|
670
|
|
|
‡a
Author's An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing
|
|
670
|
|
|
‡a
Author's An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples
|
|
670
|
|
|
‡a
Author's Analysis of erroneous data entries in paper based and electronic data collection
|
|
670
|
|
|
‡a
Author's Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms
|
|
670
|
|
|
‡a
Author's Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria
|
|
670
|
|
|
‡a
Author's Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses
|
|
670
|
|
|
‡a
Author's Antimalarial therapies in children from Papua New Guinea
|
|
670
|
|
|
‡a
Author's Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
|
|
670
|
|
|
‡a
Author's Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW.
|
|
670
|
|
|
‡a
Author's Artemisinin combination therapy for malaria: beyond good efficacy
|
|
670
|
|
|
‡a
Author's Artemisinin combination therapy for vivax malaria
|
|
670
|
|
|
‡a
Author's Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria
|
|
670
|
|
|
‡a
Author's Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
|
|
670
|
|
|
‡a
Author's Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
|
|
670
|
|
|
‡a
Author's Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction
|
|
670
|
|
|
‡a
Author's Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria
|
|
670
|
|
|
‡a
Author's "Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated
|
|
670
|
|
|
‡a
Author's Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life
|
|
670
|
|
|
‡a
Author's Barriers to routine G6PD testing prior to treatment with primaquine.
|
|
670
|
|
|
‡a
Author's Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
|
|
670
|
|
|
‡a
Author's Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group
|
|
670
|
|
|
‡a
Author's Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment
|
|
670
|
|
|
‡a
Author's Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection
|
|
670
|
|
|
‡a
Author's Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling
|
|
670
|
|
|
‡a
Author's Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow
|
|
670
|
|
|
‡a
Author's Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia
|
|
670
|
|
|
‡a
Author's Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms
|
|
670
|
|
|
‡a
Author's Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria
|
|
670
|
|
|
‡a
Author's Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria
|
|
670
|
|
|
‡a
Author's Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax
|
|
670
|
|
|
‡a
Author's Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
|
|
670
|
|
|
‡a
Author's Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum
|
|
670
|
|
|
‡a
Author's Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates
|
|
670
|
|
|
‡a
Author's Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination
|
|
670
|
|
|
‡a
Author's Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
|
|
670
|
|
|
‡a
Author's Correction: Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome.
|
|
670
|
|
|
‡a
Author's Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.
|
|
670
|
|
|
‡a
Author's Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting
|
|
670
|
|
|
‡a
Author's Decreased endothelial nitric oxide bioavailability, impaired microvascular function, and increased tissue oxygen consumption in children with falciparum malaria
|
|
670
|
|
|
‡a
Author's Defining the relationship between Plasmodium vivax parasite rate and clinical disease
|
|
670
|
|
|
‡a
Author's Detection of Mycobacterium leprae by PCR testing of sputa from a patient with pulmonary cryptococcus coinfection in northern Australia
|
|
670
|
|
|
‡a
Author's Determinants of in vitro drug susceptibility testing of Plasmodium vivax
|
|
670
|
|
|
‡a
Author's Diagnosis and treatment of Plasmodium vivax malaria
|
|
670
|
|
|
‡a
Author's Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria
|
|
670
|
|
|
‡a
Author's Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria
|
|
670
|
|
|
‡a
Author's Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy
|
|
670
|
|
|
‡a
Author's Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria
|
|
670
|
|
|
‡a
Author's Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial
|
|
670
|
|
|
‡a
Author's Drug resistant falciparum malaria: clinical consequences and strategies for prevention.
|
|
670
|
|
|
‡a
Author's Drugs that reduce transmission of falciparum malaria
|
|
670
|
|
|
‡a
Author's Early and late mortality after malaria in young children in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment
|
|
670
|
|
|
‡a
Author's Effect of early detection and treatment on malaria related maternal mortality on the north-western border of Thailand 1986-2010.
|
|
670
|
|
|
‡a
Author's Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing
|
|
670
|
|
|
‡a
Author's Effects of artemisinin derivatives on malaria transmissibility
|
|
670
|
|
|
‡a
Author's Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, o
|
|
670
|
|
|
‡a
Author's Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria.
|
|
670
|
|
|
‡a
Author's Elusive Plasmodium Species Complete the Human Malaria Genome Set
|
|
670
|
|
|
‡a
Author's Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea
|
|
670
|
|
|
‡a
Author's Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study
|
|
670
|
|
|
‡a
Author's Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax
|
|
670
|
|
|
‡a
Author's Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax
|
|
670
|
|
|
‡a
Author's Expanding the use of primaquine for the radical cure of Plasmodium vivax
|
|
670
|
|
|
‡a
Author's Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility.
|
|
670
|
|
|
‡a
Author's Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data
|
|
670
|
|
|
‡a
Author's Factors contributing to anemia after uncomplicated falciparum malaria.
|
|
670
|
|
|
‡a
Author's Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity
|
|
670
|
|
|
‡a
Author's Further Evidence of Increasing Diversity of Plasmodium vivax in the Republic of Korea in Recent Years
|
|
670
|
|
|
‡a
Author's G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study
|
|
670
|
|
|
‡a
Author's Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax
|
|
670
|
|
|
‡a
Author's Genetic analysis of Plasmodium falciparum infections on the north-western border of Thailand
|
|
670
|
|
|
‡a
Author's Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity
|
|
670
|
|
|
‡a
Author's Genetic diversity and population structure of Plasmodium vivax in Central China
|
|
670
|
|
|
‡a
Author's Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections
|
|
670
|
|
|
‡a
Author's Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics.
|
|
670
|
|
|
‡a
Author's Genomic analysis of local variation and recent evolution in Plasmodium vivax
|
|
670
|
|
|
‡a
Author's Genomic analysis of Plasmodium vivax in southern Ethiopia reveals selective pressures in multiple parasite mechanisms
|
|
670
|
|
|
‡a
Author's Genomic Analysis Reveals a Common Breakpoint in Amplifications of the Plasmodium vivax Multidrug Resistance 1 Locus in Thailand
|
|
670
|
|
|
‡a
Author's Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine
|
|
670
|
|
|
‡a
Author's Genomic epidemiology of the current wave of artemisinin resistant malaria
|
|
670
|
|
|
‡a
Author's Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Global extent of chloroquine-resistant Plasmodium vivax - Authors' reply
|
|
670
|
|
|
‡a
Author's Glycocalyx Breakdown Is Associated With Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria
|
|
670
|
|
|
‡a
Author's Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Growing evidence of Plasmodium vivax across malaria-endemic Africa
|
|
670
|
|
|
‡a
Author's High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE study).
|
|
670
|
|
|
‡a
Author's High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions
|
|
670
|
|
|
‡a
Author's High risk of Plasmodium vivax malaria following splenectomy in Papua, Indonesia.
|
|
670
|
|
|
‡a
Author's Highly effective therapy for maternal malaria associated with a lower risk of vertical transmission
|
|
670
|
|
|
‡a
Author's Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase
|
|
670
|
|
|
‡a
Author's Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria
|
|
670
|
|
|
‡a
Author's Idarubicin cardiotoxicity in acute myeloid leukaemia
|
|
670
|
|
|
‡a
Author's Identifying and combating the impacts of COVID-19 on malaria
|
|
670
|
|
|
‡a
Author's Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria
|
|
670
|
|
|
‡a
Author's Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment
|
|
670
|
|
|
‡a
Author's Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria
|
|
670
|
|
|
‡a
Author's Impaired systemic tetrahydrobiopterin bioavailability and increased dihydrobiopterin in adult falciparum malaria: association with disease severity, impaired microvascular function and increased endothelial activation
|
|
670
|
|
|
‡a
Author's Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia-Pacific region
|
|
670
|
|
|
‡a
Author's Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model
|
|
670
|
|
|
‡a
Author's Improving case definitions for severe malaria
|
|
670
|
|
|
‡a
Author's Improving the availability of artesunate for treatment of severe malaria.
|
|
670
|
|
|
‡a
Author's Improving the radical cure of Plasmodium vivax malaria
|
|
670
|
|
|
‡a
Author's In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax
|
|
670
|
|
|
‡a
Author's In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
|
|
670
|
|
|
‡a
Author's In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up
|
|
670
|
|
|
‡a
Author's In vivo parasitological measures of artemisinin susceptibility
|
|
670
|
|
|
‡a
Author's In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003.
|
|
670
|
|
|
‡a
Author's Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome
|
|
670
|
|
|
‡a
Author's Increased carboxyhemoglobin in adult falciparum malaria is associated with disease severity and mortality
|
|
670
|
|
|
‡a
Author's Inferred relatedness and heritability in malaria parasites.
|
|
670
|
|
|
‡a
Author's Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand
|
|
670
|
|
|
‡a
Author's Investigating the efficacy of triple artemisinin-based combination therapies
|
|
670
|
|
|
‡a
Author's Investigating the efficacy of triple artemisinin-based combination therapies (TACTs) for treating malaria patients using mathematical modelling
|
|
670
|
|
|
‡a
Author's KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
|
|
670
|
|
|
‡a
Author's L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial
|
|
670
|
|
|
‡a
Author's Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia
|
|
670
|
|
|
‡a
Author's Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
|
|
670
|
|
|
‡a
Author's Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in papua, Indonesia
|
|
670
|
|
|
‡a
Author's Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation
|
|
670
|
|
|
‡a
Author's Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study
|
|
670
|
|
|
‡a
Author's Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs
|
|
670
|
|
|
‡a
Author's Malaria Elimination: Time to Target All Species.
|
|
670
|
|
|
‡a
Author's Malaria eradication revisited
|
|
670
|
|
|
‡a
Author's Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study.
|
|
670
|
|
|
‡a
Author's Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum
|
|
670
|
|
|
‡a
Author's Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study
|
|
670
|
|
|
‡a
Author's Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study
|
|
670
|
|
|
‡a
Author's Maximising the public health benefit of antimalarials
|
|
670
|
|
|
‡a
Author's Mefloquine in infants and young children
|
|
670
|
|
|
‡a
Author's Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.
|
|
670
|
|
|
‡a
Author's Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
|
|
670
|
|
|
‡a
Author's Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh.
|
|
670
|
|
|
‡a
Author's Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria
|
|
670
|
|
|
‡a
Author's Molecular Epidemiology of P. vivax in Iran: High Diversity and Complex Sub-Structure Using Neutral Markers, but No Evidence of Y976F Mutation at pvmdr1.
|
|
670
|
|
|
‡a
Author's Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria
|
|
670
|
|
|
‡a
Author's Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.
|
|
670
|
|
|
‡a
Author's Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Multi-locus genotyping reveals established endemicity of a geographically distinct Plasmodium vivax population in Mauritania, West Africa
|
|
670
|
|
|
‡a
Author's Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Neurosyphilis: Still prevalent and overlooked in an at risk population
|
|
670
|
|
|
‡a
Author's New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance
|
|
670
|
|
|
‡a
Author's Nocardiosis in the Tropical Northern Territory of Australia, 1997-2014.
|
|
670
|
|
|
‡a
Author's Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum
|
|
670
|
|
|
‡a
Author's Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia
|
|
670
|
|
|
‡a
Author's Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria
|
|
670
|
|
|
‡a
Author's Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria
|
|
670
|
|
|
‡a
Author's Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection
|
|
670
|
|
|
‡a
Author's Performance and user acceptance of the Bhutan febrile and malaria information system: report from a pilot study
|
|
670
|
|
|
‡a
Author's Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Pharmacokinetics of L-arginine in adults with moderately severe malaria
|
|
670
|
|
|
‡a
Author's Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.
|
|
670
|
|
|
‡a
Author's Plasmodium falciparum activates CD16+ dendritic cells to produce TNF and IL-10 in subpatent malaria
|
|
670
|
|
|
‡a
Author's Plasmodium falciparum Activates CD16+ Dendritic Cells to Produce Tumor Necrosis Factor and Interleukin-10 in Subpatent Malaria.
|
|
670
|
|
|
‡a
Author's Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes
|
|
670
|
|
|
‡a
Author's Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine
|
|
670
|
|
|
‡a
Author's Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
|
|
670
|
|
|
‡a
Author's Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity
|
|
670
|
|
|
‡a
Author's Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution
|
|
670
|
|
|
‡a
Author's Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study
|
|
670
|
|
|
‡a
Author's Plasmodium vivax: clinical spectrum, risk factors and pathogenesis
|
|
670
|
|
|
‡a
Author's Plasmodium vivax infection: a major determinant of severe anaemia in infancy
|
|
670
|
|
|
‡a
Author's Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates.
|
|
670
|
|
|
‡a
Author's Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics
|
|
670
|
|
|
‡a
Author's Plasmodium vivax treatments: what are we looking for?
|
|
670
|
|
|
‡a
Author's Plasmodium vivax trophozoites insensitive to chloroquine
|
|
670
|
|
|
‡a
Author's Platelets kill circulating parasites of all major Plasmodium species in human malaria
|
|
670
|
|
|
‡a
Author's Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine
|
|
670
|
|
|
‡a
Author's Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.
|
|
670
|
|
|
‡a
Author's Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.
|
|
670
|
|
|
‡a
Author's Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax
|
|
670
|
|
|
‡a
Author's Potential of artemisinin-based combination therapies to block malaria transmission
|
|
670
|
|
|
‡a
Author's Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection
|
|
670
|
|
|
‡a
Author's Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory.
|
|
670
|
|
|
‡a
Author's Primaquine radical cure of Plasmodium vivax: a critical review of the literature
|
|
670
|
|
|
‡a
Author's Prolongation of the QTc interval in African children treated for falciparum malaria
|
|
670
|
|
|
‡a
Author's Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry
|
|
670
|
|
|
‡a
Author's Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.
|
|
670
|
|
|
‡a
Author's Quinolone-3-diarylethers: a new class of antimalarial drug.
|
|
670
|
|
|
‡a
Author's Rapid clinical assessment to facilitate the triage of adults with falciparum malaria, a retrospective analysis
|
|
670
|
|
|
‡a
Author's Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations
|
|
670
|
|
|
‡a
Author's Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria
|
|
670
|
|
|
‡a
Author's Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report
|
|
670
|
|
|
‡a
Author's Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Safety profile of L-arginine infusion in moderately severe falciparum malaria
|
|
670
|
|
|
‡a
Author's Severe congenital malaria acquired in utero
|
|
670
|
|
|
‡a
Author's Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial
|
|
670
|
|
|
‡a
Author's Single-dose radical cure of Plasmodium vivax: a step closer
|
|
670
|
|
|
‡a
Author's Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation
|
|
670
|
|
|
‡a
Author's Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
|
|
670
|
|
|
‡a
Author's Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency
|
|
670
|
|
|
‡a
Author's The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study
|
|
670
|
|
|
‡a
Author's The challenges of introducing routine G6PD testing into radical cure: a workshop report
|
|
670
|
|
|
‡a
Author's The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis
|
|
670
|
|
|
‡a
Author's The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
|
|
670
|
|
|
‡a
Author's The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data
|
|
670
|
|
|
‡a
Author's The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
|
|
670
|
|
|
‡a
Author's The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis
|
|
670
|
|
|
‡a
Author's The epidemiology of Plasmodium vivax. Preface
|
|
670
|
|
|
‡a
Author's The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.
|
|
670
|
|
|
‡a
Author's The global public health significance of Plasmodium vivax.
|
|
670
|
|
|
‡a
Author's The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
|
|
670
|
|
|
‡a
Author's The influence of body weight on the pharmacokinetics of mefloquine
|
|
670
|
|
|
‡a
Author's The pathophysiology of vivax malaria
|
|
670
|
|
|
‡a
Author's The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand.
|
|
670
|
|
|
‡a
Author's The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes.
|
|
670
|
|
|
‡a
Author's The relationship between age and the manifestations of and mortality associated with severe malaria
|
|
670
|
|
|
‡a
Author's The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria
|
|
670
|
|
|
‡a
Author's The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study
|
|
670
|
|
|
‡a
Author's The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
|
|
670
|
|
|
‡a
Author's The role of standby emergency medication for falciparum malaria: current opinion
|
|
670
|
|
|
‡a
Author's The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials
|
|
670
|
|
|
‡a
Author's Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Therapeutic Response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
|
|
670
|
|
|
‡a
Author's Treatment-Seeking Behavior after the Implementation of a Unified Policy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia
|
|
670
|
|
|
‡a
Author's Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades
|
|
670
|
|
|
‡a
Author's Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison
|
|
670
|
|
|
‡a
Author's Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection
|
|
670
|
|
|
‡a
Author's UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria
|
|
670
|
|
|
‡a
Author's Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
|
|
670
|
|
|
‡a
Author's Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
|
|
670
|
|
|
‡a
Author's Variation in Complexity of Infection and Transmission Stability between Neighbouring Populations of Plasmodium vivax in Southern Ethiopia
|
|
670
|
|
|
‡a
Author's Vivax malaria: a major cause of morbidity in early infancy
|
|
670
|
|
|
‡a
Author's Vivax malaria: neglected and not benign
|
|
670
|
|
|
‡a
Author's VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populations
|
|
670
|
|
|
‡a
Author's Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan
|
|
670
|
|
|
‡a
Author's Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh
|
|
670
|
|
|
‡a
Author's World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/BIBSYS|13010493
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/viaf/305038890
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/LC|no2013074810
|
|
909
|
|
|
‡a
(orcid) 0000000320002874
‡9
1
|
|
909
|
|
|
‡a
(scopus) 55544802200
‡9
1
|
|
909
|
|
|
‡a
(scopus) 7403298476
‡9
1
|
|
909
|
|
|
‡a
(scopus) 57019514500
‡9
1
|
|
912
|
|
|
‡a
novelmultiplestageantimalarialagentthatinhibitsproteinsynthesis
‡A
A novel multiple-stage antimalarial agent that inhibits protein synthesis
‡9
1
|
|
912
|
|
|
‡a
opendatasetofplasmodiumfalciparumgenomevariationin7000worldwidesamples
‡A
An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples
‡9
1
|
|
912
|
|
|
‡a
corrigendumanovelmultiplestageantimalarialagentthatinhibitsproteinsynthesis
‡A
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.
‡9
1
|
|
912
|
|
|
‡a
genomicepidemiologyofthecurrentwaveofartemisininresistantmalaria
‡A
Genomic epidemiology of the current wave of artemisinin resistant malaria
‡9
1
|
|
919
|
|
|
‡a
haematologicalconsequencesofplasmodiumvivaxmalariaafterchloroquinetreatmentwithandwithoutprimaquineaworldwideantimalarialresistancenetworksystematicreviewandindividualpatientdatametaanalysis
‡A
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
‡9
1
|
|
919
|
|
|
‡a
influenceofbodyweightonthepharmacokineticsofmefloquine
‡A
The influence of body weight on the pharmacokinetics of mefloquine
‡9
1
|
|
919
|
|
|
‡a
pathophysiologyofvivaxmalaria
‡A
The pathophysiology of vivax malaria
‡9
1
|
|
919
|
|
|
‡a
pfmdr1geneisassociatedwithamultidrugresistantphenotypeinplasmodiumfalciparumfromthewesternborderofthailand
‡A
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand.
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumtranscriptomeinseveremalariarevealsalteredexpressionofgenesinvolvedinimportantprocessesincludingsurfaceantigenencodingvargenes
‡A
The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes.
‡9
1
|
|
919
|
|
|
‡a
relationshipbetweenageandthemanifestationsofandmortalityassociatedwithseveremalaria
‡A
The relationship between age and the manifestations of and mortality associated with severe malaria
‡9
1
|
|
919
|
|
|
‡a
relationshipbetweenthehaemoglobinconcentrationandthehaematocritinplasmodiumfalciparummalaria
‡A
The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
riskofmorbidityandmortalityfollowingrecurrentmalariainpapuaindonesiaaretrospectivecohortstudy
‡A
The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study
‡9
1
|
|
919
|
|
|
‡a
riskofplasmodiumvivaxparasitaemiaafterpfalciparummalariaanindividualpatientdatametaanalysisfromtheworldwideantimalarialresistancenetwork
‡A
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
‡9
1
|
|
919
|
|
|
‡a
roleofstandbyemergencymedicationforfalciparummalariacurrentopinion
‡A
The role of standby emergency medication for falciparum malaria: current opinion
‡9
1
|
|
919
|
|
|
‡a
vivaxsurveyoronlinemappingdatabaseforplasmodiumvivaxclinicaltrials
‡A
The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials
‡9
1
|
|
919
|
|
|
‡a
therapeuticresponseofmultidrugresistantplasmodiumfalciparumandpvivaxtochloroquineandsulfadoxinepyrimethamineinsouthernpapuaindonesia
‡A
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
therapeuticresponsetodihydroartemisininpiperaquineforpfalciparumandpvivax9yearsafteritsintroductioninsouthernpapuaindonesia
‡A
Therapeutic Response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
‡A
Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
‡9
1
|
|
919
|
|
|
‡a
treatmentseekingbehavioraftertheimplementationofaunifiedpolicyofdihydroartemisininpiperaquineforthetreatmentofuncomplicatedmalariainpapuaindonesia
‡A
Treatment-Seeking Behavior after the Implementation of a Unified Policy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
treatmentseekingbehaviourandassociatedcostsformalariainpapuaindonesia
‡A
Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
trendsinmalariaresearchin11asianpacificcountriesananalysisofpeerreviewedpublicationsover2decades
‡A
Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades
‡9
1
|
|
919
|
|
|
‡a
2fixeddoseartemisinincombinationsfordrugresistantfalciparumandvivaxmalariainpapuaindonesiaanopenlabelrandomisedcomparison
‡A
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison
‡9
1
|
|
919
|
|
|
‡a
type1interferonsregulateimmuneresponsesinhumanswithbloodstageplasmodiumfalciparuminfection
‡A
Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection
‡9
1
|
|
919
|
|
|
‡a
uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria
‡A
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria
‡9
1
|
|
919
|
|
|
‡a
unsupervisedprimaquineforthetreatmentofplasmodiumvivaxmalariarelapsesinsouthernpapuaahospitalbasedcohortstudy
‡A
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
‡9
1
|
|
919
|
|
|
‡a
usingg6pdteststoenablethesafetreatmentofplasmodiumvivaxinfectionswithprimaquineonthethailandmyanmarborderacosteffectivenessanalysis
‡A
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
‡9
1
|
|
919
|
|
|
‡a
variationincomplexityofinfectionandtransmissionstabilitybetweenneighbouringpopulationsofplasmodiumvivaxinsouthernethiopia
‡A
Variation in Complexity of Infection and Transmission Stability between Neighbouring Populations of Plasmodium vivax in Southern Ethiopia
‡9
1
|
|
919
|
|
|
‡a
vivaxmalariaamajorcauseofmorbidityinearlyinfancy
‡A
Vivax malaria: a major cause of morbidity in early infancy
‡9
1
|
|
919
|
|
|
‡a
vivaxmalarianeglectedandnotbenign
‡A
Vivax malaria: neglected and not benign
‡9
1
|
|
919
|
|
|
‡a
vivaxgenanopenaccessplatformforcomparativeanalysisofshorttandemrepeatgenotypingdatainplasmodiumvivaxpopulations
‡A
VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populations
‡9
1
|
|
919
|
|
|
‡a
wherechloroquinestillworksthegeneticmakeupandsusceptibilityofplasmodiumvivaxtochloroquineplusprimaquineinbhutan
‡A
Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan
‡9
1
|
|
919
|
|
|
‡a
widerangeofg6pdactivitiesfoundamongethnicgroupsofthechittagonghilltractsbangladesh
‡A
Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh
‡9
1
|
|
919
|
|
|
‡a
worldantimalarialresistancenetwork1clinicalefficacyofantimalarialdrugs
‡A
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
‡9
1
|
|
919
|
|
|
‡a
33disubstituted55bi124triazinederivativeswithpotentinvitroandinvivoantimalarialactivity
‡A
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity
‡9
1
|
|
919
|
|
|
‡a
casecontrolauditoryevaluationofpatientstreatedwithartemisininderivativesformultidrugresistantplasmodiumfalciparummalaria
‡A
A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria.
‡9
1
|
|
919
|
|
|
‡a
comparisonof3quantitativemethodstoestimateg6pdactivityinthechittagonghilltractsbangladesh
‡A
A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh
‡9
1
|
|
919
|
|
|
‡a
longneglectedworldmalariamapplasmodiumvivaxendemicityin
‡A
A long neglected world malaria map: Plasmodium vivax endemicity in 2010
‡9
1
|
|
919
|
|
|
‡a
modelformalariatreatmentevaluationinthepresenceofmultiplespecies
‡A
A model for malaria treatment evaluation in the presence of multiple species
‡9
1
|
|
919
|
|
|
‡a
newplasmodiumvivaxreferencesequencewithimprovedassemblyofthesubtelomeresrevealsanabundanceofpirgenes
‡A
A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes
‡9
1
|
|
919
|
|
|
‡a
randomizedpilotstudyof50arginineinfusioninseverefalciparummalariapreliminarysafetyefficacyandpharmacokinetics
‡A
A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics
‡9
1
|
|
919
|
|
|
‡a
simplescoretopredicttheoutcomeofseveremalariainadults
‡A
A simple score to predict the outcome of severe malaria in adults
‡9
1
|
|
919
|
|
|
‡a
studyofthetnfltaltblocusandsusceptibilitytoseveremalariainhighlandpapuanchildrenandadults
‡A
A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults
‡9
1
|
|
919
|
|
|
‡a
systematicreviewofpublishedantimalarialclinicaltrialsparasiteclearanceofartemisinincontainingregimensinthetreatmentofuncomplicatedmalaria
‡A
A systematic review of published antimalarial clinical trials: parasite clearance of artemisinin-containing regimens in the treatment of uncomplicated malaria
‡9
1
|
|
919
|
|
|
‡a
systematicreviewofsubmicroscopicplasmodiumvivaxinfection
‡A
A systematic review of sub-microscopic Plasmodium vivax infection
‡9
1
|
|
919
|
|
|
‡a
tetraoxanebasedantimalarialdrugcandidatethatovercomespfk13c580ydependentartemisininresistance
‡A
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
‡9
1
|
|
919
|
|
|
‡a
triazolopyrimidinebaseddihydroorotatedehydrogenaseinhibitor
‡A
A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor
‡9
1
|
|
919
|
|
|
‡a
triazolopyrimidinebaseddihydroorotatedehydrogenaseinhibitordsm421withimproveddruglikepropertiesfortreatmentandpreventionofmalaria
‡A
A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria
‡9
1
|
|
919
|
|
|
‡a
advancesinparasitologypreface
‡A
Advances in Parasitology. Preface
‡9
1
|
|
919
|
|
|
‡a
adverseeffectsofmefloquineforthetreatmentofuncomplicatedmalariainthailandapooledanalysisof19850individualpatients
‡A
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients
‡9
1
|
|
919
|
|
|
‡a
adversepregnancyoutcomesinanareawheremultidrugresistantplasmodiumvivaxandplasmodiumfalciparuminfectionsareendemic
‡A
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic
‡9
1
|
|
919
|
|
|
‡a
agerelatedsusceptibilitytoseveremalariaassociatedwithgalectin2inhighlandpapuans
‡A
Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans
‡9
1
|
|
919
|
|
|
‡a
amplificationofpvmdr1associatedwithmultidrugresistantplasmodiumvivax
‡A
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
analyticalmethodforassessingstagespecificdrugactivityinplasmodiumvivaxmalariaimplicationsforexvivodrugsusceptibilitytesting
‡A
An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing
‡9
1
|
|
919
|
|
|
‡a
analysisoferroneousdataentriesinpaperbasedandelectronicdatacollection
‡A
Analysis of erroneous data entries in paper based and electronic data collection
‡9
1
|
|
919
|
|
|
‡a
analysisofexvivodrugresponsedataofplasmodiumclinicalisolatestheprosandconsofdifferentcomputerprogramsandonlineplatforms
‡A
Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms
‡9
1
|
|
919
|
|
|
‡a
angiopoietin2isassociatedwithdecreasedendothelialnitricoxideandpoorclinicaloutcomeinseverefalciparummalaria
‡A
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
antibodiestoplasmodiumfalciparumandplasmodiumvivaxmerozoitesurfaceprotein5inindonesiaspeciesspecificandcrossreactiveresponses
‡A
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses
‡9
1
|
|
919
|
|
|
‡a
antimalarialtherapiesinchildrenfrompapuanewguinea
‡A
Antimalarial therapies in children from Papua New Guinea
‡9
1
|
|
919
|
|
|
‡a
artemetherlumefantrinedosingformalariatreatmentinyoungchildrenandpregnantwomenapharmacokineticpharmacodynamicmetaanalysis
‡A
Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
artemetherlumefantrineversuschloroquineforthetreatmentofuncomplicatedplasmodiumknowlesimalariaanopenlabelrandomizedcontrolledtrialcanknow
‡A
Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW.
‡9
1
|
|
919
|
|
|
‡a
artemisinincombinationtherapyformalariabeyondgoodefficacy
‡A
Artemisinin combination therapy for malaria: beyond good efficacy
‡9
1
|
|
919
|
|
|
‡a
artemisinincombinationtherapyforvivaxmalaria
‡A
Artemisinin combination therapy for vivax malaria
‡9
1
|
|
919
|
|
|
‡a
artesunateandmefloquineinthetreatmentofuncomplicatedmultidrugresistanthyperparasitaemicfalciparummalaria
‡A
Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
artesunatemefloquineversuschloroquinefortreatmentofuncomplicatedplasmodiumknowlesimalariainmalaysiaactknowanopenlabelrandomisedcontrolledtrial
‡A
Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
assessingtheutilityofanantimalarialpharmacokineticpharmacodynamicmodelforaidingdrugclinicaldevelopment
‡A
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
‡9
1
|
|
919
|
|
|
‡a
assessmentofpfmdr1genecopynumberbytandemcompetitivepolymerasechainreaction
‡A
Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction
‡9
1
|
|
919
|
|
|
‡a
assessmentoftherapeuticresponsestogametocytocidaldrugsinplasmodiumfalciparummalaria
‡A
Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
asymptomaticmalariaachronicanddebilitatinginfectionthatshouldbetreated
‡A
"Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated
‡9
1
|
|
919
|
|
|
‡a
asymptomaticvivaxandfalciparumparasitaemiawithhelminthcoinfectionmajorriskfactorsforanaemiainearlylife
‡A
Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life
‡9
1
|
|
919
|
|
|
‡a
barrierstoroutineg6pdtestingpriortotreatmentwithprimaquine
‡A
Barriers to routine G6PD testing prior to treatment with primaquine.
‡9
1
|
|
919
|
|
|
‡a
baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
‡A
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
‡9
1
|
|
919
|
|
|
‡a
challengesforachievingsafeandeffectiveradicalcureofplasmodiumvivaxaroundtablediscussionoftheapmenvivaxworkinggroup
‡A
Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group
‡9
1
|
|
919
|
|
|
‡a
changesinthetreatmentresponsestoartesunatemefloquineonthenorthwesternborderofthailandduring13yearsofcontinuousdeployment
‡A
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment
‡9
1
|
|
919
|
|
|
‡a
characterizationofblooddendriticandregulatorytcellsinasymptomaticadultswithsubmicroscopicplasmodiumfalciparumorplasmodiumvivaxinfection
‡A
Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection
‡9
1
|
|
919
|
|
|
‡a
characterizationofnovelantimalarialcompoundact451840preclinicalassessmentofactivityanddoseefficacymodeling
‡A
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling
‡9
1
|
|
919
|
|
|
‡a
chloroquineefficacyforplasmodiumvivaxinmyanmarinpopulationswithhighgeneticdiversityandmoderateparasitegeneflow
‡A
Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow
‡9
1
|
|
919
|
|
|
‡a
chloroquineefficacyforplasmodiumvivaxmalariatreatmentinsouthernethiopia
‡A
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia
‡9
1
|
|
919
|
|
|
‡a
chloroquineresistantplasmodiumvivaxinvitrocharacterisationandassociationwithmolecularpolymorphisms
‡A
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms
‡9
1
|
|
919
|
|
|
‡a
circulatingneutrophilextracellulartrapsandneutrophilactivationareincreasedinproportiontodiseaseseverityinhumanmalaria
‡A
Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria
‡9
1
|
|
919
|
|
|
‡a
clinicalandpharmacologicaldeterminantsofthetherapeuticresponsetodihydroartemisininpiperaquinefordrugresistantmalaria
‡A
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria
‡9
1
|
|
919
|
|
|
‡a
comaassociatedwithmicroscopydiagnosedplasmodiumvivaxaprospectivestudyinpapuaindonesia
‡A
Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
comparativeexvivoactivityofnovelendoperoxidesinmultidrugresistantplasmodiumfalciparumandpvivax
‡A
Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax
‡9
1
|
|
919
|
|
|
‡a
comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial
‡A
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
comparisonof3molecularmethodsforthedetectionandspeciationofplasmodiumvivaxandplasmodiumfalciparum
‡A
Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum
‡9
1
|
|
919
|
|
|
‡a
contrastingexvivoefficaciesofreversedchloroquinecompoundsinchloroquineresistantplasmodiumfalciparumandpvivaxisolates
‡A
Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates
‡9
1
|
|
919
|
|
|
‡a
contrastingtransmissiondynamicsofcoendemicplasmodiumvivaxandpfalciparumimplicationsformalariacontrolandelimination
‡A
Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination
‡9
1
|
|
919
|
|
|
‡a
correctioncomparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial
‡A
Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
correctionincreasedasymmetricdimethylarginineinseverefalciparummalariaassociationwithimpairednitricoxidebioavailabilityandfataloutcome
‡A
Correction: Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome.
‡9
1
|
|
919
|
|
|
‡a
dealingwithindeterminateoutcomesinantimalarialdrugefficacytrialsacomparisonbetweencompletecaseanalysismultipleimputationandinverseprobabilityweighting
‡A
Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting
‡9
1
|
|
919
|
|
|
‡a
decreasedendothelialnitricoxidebioavailabilityimpairedmicrovascularfunctionandincreasedtissueoxygenconsumptioninchildrenwithfalciparummalaria
‡A
Decreased endothelial nitric oxide bioavailability, impaired microvascular function, and increased tissue oxygen consumption in children with falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
definingtherelationshipbetweenplasmodiumvivaxparasiterateandclinicaldisease
‡A
Defining the relationship between Plasmodium vivax parasite rate and clinical disease
‡9
1
|
|
919
|
|
|
‡a
detectionofmycobacteriumlepraebypcrtestingofsputafromapatientwithpulmonarycryptococcuscoinfectioninnorthernaustralia
‡A
Detection of Mycobacterium leprae by PCR testing of sputa from a patient with pulmonary cryptococcus coinfection in northern Australia
‡9
1
|
|
919
|
|
|
‡a
determinantsofinvitrodrugsusceptibilitytestingofplasmodiumvivax
‡A
Determinants of in vitro drug susceptibility testing of Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
diagnosisandtreatmentofplasmodiumvivaxmalaria
‡A
Diagnosis and treatment of Plasmodium vivax malaria
‡9
1
|
|
919
|
|
|
‡a
differencesinpfemp1srecognizedbyantibodiesfrompatientswithuncomplicatedorseveremalaria
‡A
Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria
‡9
1
|
|
919
|
|
|
‡a
differentialcellularrecognitionofantigensduringacuteplasmodiumfalciparumandplasmodiumvivaxmalaria
‡A
Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria
‡9
1
|
|
919
|
|
|
‡a
dihydroartemisininpiperaquinetreatmentofmultidrugresistantfalciparumandvivaxmalariainpregnancy
‡A
Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy
‡9
1
|
|
919
|
|
|
‡a
dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria
‡A
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria
‡9
1
|
|
919
|
|
|
‡a
dihydroartemisininpiperaquineversuschloroquineinthetreatmentofplasmodiumvivaxmalariainthailandarandomizedcontrolledtrial
‡A
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
drugresistantfalciparummalariaclinicalconsequencesandstrategiesforprevention
‡A
Drug resistant falciparum malaria: clinical consequences and strategies for prevention.
‡9
1
|
|
919
|
|
|
‡a
drugsthatreducetransmissionoffalciparummalaria
‡A
Drugs that reduce transmission of falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
earlyandlatemortalityaftermalariainyoungchildreninpapuaindonesia
‡A
Early and late mortality after malaria in young children in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
earlyvomitingofmefloquineinchildrenwithmalariaisnotmodifiedbythetimingofantipyretictreatment
‡A
Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment
‡9
1
|
|
919
|
|
|
‡a
effectofearlydetectionandtreatmentonmalariarelatedmaternalmortalityonthenorthwesternborderofthailand1986
‡A
Effect of early detection and treatment on malaria related maternal mortality on the north-western border of Thailand 1986-2010.
‡9
1
|
|
919
|
|
|
‡a
effectivepreparationofplasmodiumvivaxfieldisolatesforhighthroughputwholegenomesequencing
‡A
Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing
‡9
1
|
|
919
|
|
|
‡a
effectsofartemisininderivativesonmalariatransmissibility
‡A
Effects of artemisinin derivatives on malaria transmissibility
‡9
1
|
|
919
|
|
|
‡a
efficacyandsafetyofintermittentpreventivetreatmentandintermittentscreeningandtreatmentversussinglescreeningandtreatmentwithdihydroartemisininpiperaquineforthecontrolofmalariainpregnancyinindonesiaaclusterrandomisedo
‡A
Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, o
‡9
1
|
|
919
|
|
|
‡a
electrocardiographicsafetyevaluationofdihydroartemisininpiperaquineinthetreatmentofuncomplicatedfalciparummalaria
‡A
Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria.
‡9
1
|
|
919
|
|
|
‡a
elusiveplasmodiumspeciescompletethehumanmalariagenomeset
‡A
Elusive Plasmodium Species Complete the Human Malaria Genome Set
‡9
1
|
|
919
|
|
|
‡a
emergenceofartemisininresistantplasmodiumfalciparumwithkelch13c580ymutationsontheislandofnewguinea
‡A
Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea
‡9
1
|
|
919
|
|
|
‡a
evaluatingantimalarialefficacyinsinglearmedandcomparativedrugtrialsusingcompetingrisksurvivalanalysisasimulationstudy
‡A
Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study
‡9
1
|
|
919
|
|
|
‡a
exvivoactivityofhistonedeacetylaseinhibitorsagainstmultidrugresistantclinicalisolatesofplasmodiumfalciparumandpvivax
‡A
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax
‡9
1
|
|
919
|
|
|
‡a
exvivodrugsusceptibilityofferroquineagainstchloroquineresistantisolatesofplasmodiumfalciparumandpvivax
‡A
Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax
‡9
1
|
|
919
|
|
|
‡a
expandingtheuseofprimaquinefortheradicalcureofplasmodiumvivax
‡A
Expanding the use of primaquine for the radical cure of Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
expressionofplasmodiumvivaxcrtoisrelatedtoparasitestagebutnotexvivochloroquinesusceptibility
‡A
Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility.
‡9
1
|
|
919
|
|
|
‡a
factorsaffectingtheelectrocardiographicqtintervalinmalariaasystematicreviewandmetaanalysisofindividualpatientdata
‡A
Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data
‡9
1
|
|
919
|
|
|
‡a
factorscontributingtoanemiaafteruncomplicatedfalciparummalaria
‡A
Factors contributing to anemia after uncomplicated falciparum malaria.
‡9
1
|
|
919
|
|
|
‡a
fieldevaluationofquantitativepointofcarediagnosticstomeasureglucose6phosphatedehydrogenaseactivity
‡A
Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity
‡9
1
|
|
919
|
|
|
‡a
furtherevidenceofincreasingdiversityofplasmodiumvivaxintherepublicofkoreainrecentyears
‡A
Further Evidence of Increasing Diversity of Plasmodium vivax in the Republic of Korea in Recent Years
‡9
1
|
|
919
|
|
|
‡a
g6pddeficiencyandantimalarialefficacyforuncomplicatedmalariainbangladeshaprospectiveobservationalstudy
‡A
G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study
‡9
1
|
|
919
|
|
|
‡a
gametocytedynamicsandtheroleofdrugsinreducingthetransmissionpotentialofplasmodiumvivax
‡A
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
geneticanalysisofplasmodiumfalciparuminfectionsonthenorthwesternborderofthailand
‡A
Genetic analysis of Plasmodium falciparum infections on the north-western border of Thailand
‡9
1
|
|
919
|
|
|
‡a
geneticdiversityandneutralselectioninplasmodiumvivaxerythrocytebindingproteincorrelateswithpatientantigenicity
‡A
Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity
‡9
1
|
|
919
|
|
|
‡a
geneticdiversityandpopulationstructureofplasmodiumvivaxincentralchina
‡A
Genetic diversity and population structure of Plasmodium vivax in Central China
‡9
1
|
|
919
|
|
|
‡a
geneticmicroepidemiologyofmalariainpapuaindonesiaextensivepvivaxdiversityandadistinctsubpopulationofasymptomaticpfalciparuminfections
‡A
Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections
‡9
1
|
|
919
|
|
|
‡a
genomicanalysisofapreeliminationmalaysianplasmodiumvivaxpopulationrevealsselectivepressuresandchangingtransmissiondynamics
‡A
Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics.
‡9
1
|
|
919
|
|
|
‡a
genomicanalysisoflocalvariationandrecentevolutioninplasmodiumvivax
‡A
Genomic analysis of local variation and recent evolution in Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
genomicanalysisofplasmodiumvivaxinsouthernethiopiarevealsselectivepressuresinmultipleparasitemechanisms
‡A
Genomic analysis of Plasmodium vivax in southern Ethiopia reveals selective pressures in multiple parasite mechanisms
‡9
1
|
|
919
|
|
|
‡a
genomicanalysisrevealsacommonbreakpointinamplificationsoftheplasmodiumvivaxmultidrugresistance1locusinthailand
‡A
Genomic Analysis Reveals a Common Breakpoint in Amplifications of the Plasmodium vivax Multidrug Resistance 1 Locus in Thailand
‡9
1
|
|
919
|
|
|
‡a
genomiccharacterizationofrecrudescentplasmodiummalariaeaftertreatmentwithartemetherlumefantrine
‡A
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine
‡9
1
|
|
919
|
|
|
‡a
globalextentofchloroquineresistantplasmodiumvivaxasystematicreviewandmetaanalysis
‡A
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
globalextentofchloroquineresistantplasmodiumvivaxauthorsreply
‡A
Global extent of chloroquine-resistant Plasmodium vivax - Authors' reply
‡9
1
|
|
919
|
|
|
‡a
glycocalyxbreakdownisassociatedwithseverediseaseandfataloutcomeinplasmodiumfalciparummalaria
‡A
Glycocalyx Breakdown Is Associated With Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria
‡9
1
|
|
919
|
|
|
‡a
greaterendothelialactivationweibelpaladebodyreleaseandhostinflammatoryresponsetoplasmodiumvivaxcomparedwithplasmodiumfalciparumaprospectivestudyinpapuaindonesia
‡A
Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
growingevidenceofplasmodiumvivaxacrossmalariaendemicafrica
‡A
Growing evidence of Plasmodium vivax across malaria-endemic Africa
‡9
1
|
|
919
|
|
|
‡a
highburdenofdiabeticfootinfectionsinthetopendofaustraliaanemerginghealthcrisisdefinestudy
‡A
High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE study).
‡9
1
|
|
919
|
|
|
‡a
highdeformabilityofplasmodiumvivaxinfectedredbloodcellsundermicrofluidicconditions
‡A
High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions
‡9
1
|
|
919
|
|
|
‡a
highriskofplasmodiumvivaxmalariafollowingsplenectomyinpapuaindonesia
‡A
High risk of Plasmodium vivax malaria following splenectomy in Papua, Indonesia.
‡9
1
|
|
919
|
|
|
‡a
highlyeffectivetherapyformaternalmalariaassociatedwithalowerriskofverticaltransmission
‡A
Highly effective therapy for maternal malaria associated with a lower risk of vertical transmission
‡9
1
|
|
919
|
|
|
‡a
humantcellrecognitionofthebloodstageantigenplasmodiumhypoxanthineguaninexanthinephosphoribosyltransferase
‡A
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase
‡9
1
|
|
919
|
|
|
‡a
humantcellrecognitionofthebloodstageantigenplasmodiumhypoxanthineguaninexanthinephosphoribosyltransferasehgxprtinacutemalaria
‡A
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria
‡9
1
|
|
919
|
|
|
‡a
idarubicincardiotoxicityinacutemyeloidleukaemia
‡A
Idarubicin cardiotoxicity in acute myeloid leukaemia
‡9
1
|
|
919
|
|
|
‡a
identifyingandcombatingtheimpactsofcovid19onmalaria
‡A
Identifying and combating the impacts of COVID-19 on malaria
‡9
1
|
|
919
|
|
|
‡a
impairednitricoxidebioavailabilityand50argininereversibleendothelialdysfunctioninadultswithfalciparummalaria
‡A
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
impairedpulmonarynitricoxidebioavailabilityinpulmonarytuberculosisassociationwithdiseaseseverityanddelayedmycobacterialclearancewithtreatment
‡A
Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment
‡9
1
|
|
919
|
|
|
‡a
impairedskeletalmusclemicrovascularfunctionandincreasedskeletalmuscleoxygenconsumptioninseverefalciparummalaria
‡A
Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
impairedsystemictetrahydrobiopterinbioavailabilityandincreaseddihydrobiopterininadultfalciparummalariaassociationwithdiseaseseverityimpairedmicrovascularfunctionandincreasedendothelialactivation
‡A
Impaired systemic tetrahydrobiopterin bioavailability and increased dihydrobiopterin in adult falciparum malaria: association with disease severity, impaired microvascular function and increased endothelial activation
‡9
1
|
|
919
|
|
|
‡a
implementingparasitegenotypingintonationalsurveillanceframeworksfeedbackfromcontrolprogrammesandresearchersintheasiapacificregion
‡A
Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia-Pacific region
‡9
1
|
|
919
|
|
|
‡a
implicationsofpopulationlevelimmunityfortheemergenceofartemisininresistantmalariaamathematicalmodel
‡A
Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model
‡9
1
|
|
919
|
|
|
‡a
improvingcasedefinitionsforseveremalaria
‡A
Improving case definitions for severe malaria
‡9
1
|
|
919
|
|
|
‡a
improvingtheavailabilityofartesunatefortreatmentofseveremalaria
‡A
Improving the availability of artesunate for treatment of severe malaria.
‡9
1
|
|
919
|
|
|
‡a
improvingtheradicalcureofplasmodiumvivaxmalaria
‡A
Improving the radical cure of Plasmodium vivax malaria
‡9
1
|
|
919
|
|
|
‡a
invitroactivityofpyronaridineagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivax
‡A
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
invivoandinvitroefficacyofamodiaquinemonotherapyfortreatmentofinfectionbychloroquineresistantplasmodiumvivax
‡A
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
‡9
1
|
|
919
|
|
|
‡a
invivoandinvitroefficacyofchloroquineagainstplasmodiummalariaeandpovaleinpapuaindonesia
‡A
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
invivoassessmentofdrugefficacyagainstplasmodiumfalciparummalariadurationoffollowup
‡A
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up
‡9
1
|
|
919
|
|
|
‡a
invivoparasitologicalmeasuresofartemisininsusceptibility
‡A
In vivo parasitological measures of artemisinin susceptibility
‡9
1
|
|
919
|
|
|
‡a
invivosensitivitymonitoringofmefloquinemonotherapyandartesunatemefloquinecombinationsforthetreatmentofuncomplicatedfalciparummalariainthailandin
‡A
In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003.
‡9
1
|
|
919
|
|
|
‡a
increasedasymmetricdimethylarginineinseverefalciparummalariaassociationwithimpairednitricoxidebioavailabilityandfataloutcome
‡A
Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome
‡9
1
|
|
919
|
|
|
‡a
increasedcarboxyhemoglobininadultfalciparummalariaisassociatedwithdiseaseseverityandmortality
‡A
Increased carboxyhemoglobin in adult falciparum malaria is associated with disease severity and mortality
‡9
1
|
|
919
|
|
|
‡a
inferredrelatednessandheritabilityinmalariaparasites
‡A
Inferred relatedness and heritability in malaria parasites.
‡9
1
|
|
919
|
|
|
‡a
intrahostselectionofplasmodiumfalciparumpfmdr1allelesafterantimalarialtreatmentonthenorthwesternborderofthailand
‡A
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand
‡9
1
|
|
919
|
|
|
‡a
investigatingtheefficacyoftripleartemisininbasedcombinationtherapies
‡A
Investigating the efficacy of triple artemisinin-based combination therapies
‡9
1
|
|
919
|
|
|
‡a
investigatingtheefficacyoftripleartemisininbasedcombinationtherapiestactsfortreatingmalariapatientsusingmathematicalmodelling
‡A
Investigating the efficacy of triple artemisinin-based combination therapies (TACTs) for treating malaria patients using mathematical modelling
‡9
1
|
|
919
|
|
|
‡a
kaf156isanantimalarialclinicalcandidatewithpotentialforuseinprophylaxistreatmentandpreventionofdiseasetransmission
‡A
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
‡9
1
|
|
919
|
|
|
‡a
arginineandvitamin500adjunctivetherapiesinpulmonarytuberculosisarandomiseddoubleblindplacebocontrolledtrial
‡A
L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial
‡9
1
|
|
919
|
|
|
‡a
lossofcomplementregulatoryproteinsonuninfectederythrocytesinvivaxandfalciparummalariaanemia
‡A
Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia
‡9
1
|
|
919
|
|
|
‡a
lowriskofrecurrencefollowingartesunatesulphadoxinepyrimethamineplusprimaquineforuncomplicatedplasmodiumfalciparumandplasmodiumvivaxinfectionsintherepublicofthesudan
‡A
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
‡9
1
|
|
919
|
|
|
‡a
lunginjuryinuncomplicatedandseverefalciparummalariaalongitudinalstudyinpapuaindonesia
‡A
Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
lunginjuryinvivaxmalariapathophysiologicalevidenceforpulmonaryvascularsequestrationandposttreatmentalveolarcapillaryinflammation
‡A
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation
‡9
1
|
|
919
|
|
|
‡a
majorburdenofsevereanemiafromnonfalciparummalariaspeciesinsouthernpapuaahospitalbasedsurveillancestudy
‡A
Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study
‡9
1
|
|
919
|
|
|
‡a
makingthemostofclinicaldatareviewingtheroleofpharmacokineticpharmacodynamicmodelsofantimalarialdrugs
‡A
Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs
‡9
1
|
|
919
|
|
|
‡a
malariaeliminationtimetotargetallspecies
‡A
Malaria Elimination: Time to Target All Species.
‡9
1
|
|
919
|
|
|
‡a
malariaeradicationrevisited
‡A
Malaria eradication revisited
‡9
1
|
|
919
|
|
|
‡a
malariamorbidityandmortalityfollowingintroductionofauniversalpolicyofartemisininbasedtreatmentformalariainpapuaindonesiaalongitudinalsurveillancestudy
‡A
Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study.
‡9
1
|
|
919
|
|
|
‡a
malariamorbidityinpapuaindonesiaanareawithmultidrugresistantplasmodiumvivaxandplasmodiumfalciparum
‡A
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum
‡9
1
|
|
919
|
|
|
‡a
malariarelatedhospitalizationduringchildhoodinpapuaindonesiaaretrospectivecohortstudy
‡A
Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study
‡9
1
|
|
919
|
|
|
‡a
mappingtheglobalendemicityandclinicalburdenofplasmodiumvivax200017aspatialandtemporalmodellingstudy
‡A
Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study
‡9
1
|
|
919
|
|
|
‡a
maximisingthepublichealthbenefitofantimalarials
‡A
Maximising the public health benefit of antimalarials
‡9
1
|
|
919
|
|
|
‡a
mefloquineininfantsandyoungchildren
‡A
Mefloquine in infants and young children
‡9
1
|
|
919
|
|
|
‡a
mefloquinepharmacokineticpharmacodynamicmodelsimplicationsfordosingandresistance
‡A
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.
‡9
1
|
|
919
|
|
|
‡a
mefloquineresistanceinplasmodiumfalciparumandincreasedpfmdr1genecopynumber
‡A
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
‡9
1
|
|
919
|
|
|
‡a
molecularanalysisdemonstrateshighprevalenceofchloroquineresistancebutnoevidenceofartemisininresistanceinplasmodiumfalciparuminthechittagonghilltractsofbangladesh
‡A
Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh.
‡9
1
|
|
919
|
|
|
‡a
molecularandpharmacologicaldeterminantsofthetherapeuticresponsetoartemetherlumefantrineinmultidrugresistantplasmodiumfalciparummalaria
‡A
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
molecularepidemiologyofpvivaxiniranhighdiversityandcomplexsubstructureusingneutralmarkersbutnoevidenceofy976fmutationatpvmdr1
‡A
Molecular Epidemiology of P. vivax in Iran: High Diversity and Complex Sub-Structure Using Neutral Markers, but No Evidence of Y976F Mutation at pvmdr1.
‡9
1
|
|
919
|
|
|
‡a
molecularprofilingrevealsfeaturesofclinicalimmunityandimmunosuppressioninasymptomaticpfalciparummalaria
‡A
Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
molecularsurveillanceover14yearsconfirmsreductionofplasmodiumvivaxandfalciparumtransmissionafterimplementationofartemisininbasedcombinationtherapyinpapuaindonesia
‡A
Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
monitoringantimalarialdrugresistanceapplyinglessonslearnedfromthepastinafastmovingpresent
‡A
Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.
‡9
1
|
|
919
|
|
|
‡a
mortalityattributabletoplasmodiumvivaxmalariaaclinicalauditfrompapuaindonesia
‡A
Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
multilocusgenotypingrevealsestablishedendemicityofageographicallydistinctplasmodiumvivaxpopulationinmauritaniawestafrica
‡A
Multi-locus genotyping reveals established endemicity of a geographically distinct Plasmodium vivax population in Mauritania, West Africa
‡9
1
|
|
919
|
|
|
‡a
multidrugresistantplasmodiumvivaxassociatedwithsevereandfatalmalariaaprospectivestudyinpapuaindonesia
‡A
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
neurosyphilisstillprevalentandoverlookedinanatriskpopulation
‡A
Neurosyphilis: Still prevalent and overlooked in an at risk population
‡9
1
|
|
919
|
|
|
‡a
newdevelopmentsinplasmodiumvivaxmalariaseverediseaseandtheriseofchloroquineresistance
‡A
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance
‡9
1
|
|
919
|
|
|
‡a
nocardiosisinthetropicalnorthernterritoryofaustralia1997
‡A
Nocardiosis in the Tropical Northern Territory of Australia, 1997-2014.
‡9
1
|
|
919
|
|
|
‡a
nonlinearmixedeffectsmodellingofinvitrodrugsusceptibilityandmolecularcorrelatesofmultidrugresistantplasmodiumfalciparum
‡A
Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum
‡9
1
|
|
919
|
|
|
‡a
optimalhealthanddiseasemanagementusingspatialuncertaintyageographiccharacterizationofemergentartemisininresistantplasmodiumfalciparumdistributionsinsoutheastasia
‡A
Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia
‡9
1
|
|
919
|
|
|
‡a
parasitebiomassrelatedinflammationendothelialactivationmicrovasculardysfunctionanddiseaseseverityinvivaxmalaria
‡A
Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria
‡9
1
|
|
919
|
|
|
‡a
parasitedependentexpansionoftnfreceptor2positiveregulatorytcellswithenhancedsuppressiveactivityinadultswithseveremalaria
‡A
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria
‡9
1
|
|
919
|
|
|
‡a
passivelyversusactivelydetectedmalariasimilargeneticdiversitybutdifferentcomplexityofinfection
‡A
Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection
‡9
1
|
|
919
|
|
|
‡a
performanceanduseracceptanceofthebhutanfebrileandmalariainformationsystemreportfromapilotstudy
‡A
Performance and user acceptance of the Bhutan febrile and malaria information system: report from a pilot study
‡9
1
|
|
919
|
|
|
‡a
performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
‡A
Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
pharmacokineticsof50arginineinadultswithmoderatelyseveremalaria
‡A
Pharmacokinetics of L-arginine in adults with moderately severe malaria
‡9
1
|
|
919
|
|
|
‡a
phenotypicandgenotypiccharacterisationofdrugresistantplasmodiumvivax
‡A
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumactivatescd16+dendriticcellstoproducetnfandil10insubpatentmalaria
‡A
Plasmodium falciparum activates CD16+ dendritic cells to produce TNF and IL-10 in subpatent malaria
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumactivatescd16+dendriticcellstoproducetumornecrosisfactorandinterleukin10insubpatentmalaria
‡A
Plasmodium falciparum Activates CD16+ Dendritic Cells to Produce Tumor Necrosis Factor and Interleukin-10 in Subpatent Malaria.
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumandplasmodiumvivaxdemonstratecontrastingchloroquineresistancereversalphenotypes
‡A
Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumantimalarialdrugsusceptibilityonthenorthwesternborderofthailandduring5yearsofextensiveuseofartesunatemefloquine
‡A
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumartemisininresistancemonitoringinsabahmalaysiainvivotherapeuticefficacyandkelch13molecularmarkersurveillance
‡A
Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
‡9
1
|
|
919
|
|
|
‡a
plasmodiumfalciparumgametocytedynamicsinareasofdifferentmalariaendemicity
‡A
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity
‡9
1
|
|
919
|
|
|
‡a
plasmodiummalariaeandpovalegenomesprovideinsightsintomalariaparasiteevolution
‡A
Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution
‡9
1
|
|
919
|
|
|
‡a
plasmodiummalariaeinfectionassociatedwithahighburdenofanemiaahospitalbasedsurveillancestudy
‡A
Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study
‡9
1
|
|
919
|
|
|
‡a
plasmodiumvivaxclinicalspectrumriskfactorsandpathogenesis
‡A
Plasmodium vivax: clinical spectrum, risk factors and pathogenesis
‡9
1
|
|
919
|
|
|
‡a
plasmodiumvivaxinfectionamajordeterminantofsevereanaemiaininfancy
‡A
Plasmodium vivax infection: a major determinant of severe anaemia in infancy
‡9
1
|
|
919
|
|
|
‡a
plasmodiumvivaxisotopicpicogreenandmicroscopicassaysformeasuringchloroquinesensitivityinfreshandcryopreservedisolates
‡A
Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates.
‡9
1
|
|
919
|
|
|
‡a
plasmodiumvivaxrecurrencefollowingfalciparumandmixedspeciesmalariariskfactorsandeffectofantimalarialkinetics
‡A
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics
‡9
1
|
|
919
|
|
|
‡a
plasmodiumvivaxtreatmentswhatarewelookingfor
‡A
Plasmodium vivax treatments: what are we looking for?
‡9
1
|
|
919
|
|
|
‡a
plasmodiumvivaxtrophozoitesinsensitivetochloroquine
‡A
Plasmodium vivax trophozoites insensitive to chloroquine
‡9
1
|
|
919
|
|
|
‡a
plateletskillcirculatingparasitesofallmajorplasmodiumspeciesinhumanmalaria
‡A
Platelets kill circulating parasites of all major Plasmodium species in human malaria
‡9
1
|
|
919
|
|
|
‡a
polymorphismsinplasmodiumfalciparumchloroquineresistancetransporterandmultidrugresistance1genesparasiteriskfactorsthataffecttreatmentoutcomesforpfalciparummalariaafterartemetherlumefantrineandartesunateamodiaquine
‡A
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine
‡9
1
|
|
919
|
|
|
‡a
populationpharmacokineticpropertiesofpiperaquineinfalciparummalariaanindividualparticipantdatametaanalysis
‡A
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.
‡9
1
|
|
919
|
|
|
‡a
populationpharmacokineticsofintravenousartesunateapooledanalysisofindividualdatafrompatientswithseveremalaria
‡A
Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.
‡9
1
|
|
919
|
|
|
‡a
potentexvivoactivityofnaphthoquineandmethyleneblueagainstdrugresistantclinicalisolatesofplasmodiumfalciparumandplasmodiumvivax
‡A
Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax
‡9
1
|
|
919
|
|
|
‡a
potentialofartemisininbasedcombinationtherapiestoblockmalariatransmission
‡A
Potential of artemisinin-based combination therapies to block malaria transmission
‡9
1
|
|
919
|
|
|
‡a
preserveddendriticcellhladrexpressionandreducedregulatorytcellactivationinasymptomaticplasmodiumfalciparumandpvivaxinfection
‡A
Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection
‡9
1
|
|
919
|
|
|
‡a
preventionofopportunisticinfectionsinimmunosuppressedpatientsinthetropicaltopendofthenorthernterritory
‡A
Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory.
‡9
1
|
|
919
|
|
|
‡a
primaquineradicalcureofplasmodiumvivaxacriticalreviewoftheliterature
‡A
Primaquine radical cure of Plasmodium vivax: a critical review of the literature
‡9
1
|
|
919
|
|
|
‡a
prolongationoftheqtcintervalinafricanchildrentreatedforfalciparummalaria
‡A
Prolongation of the QTc interval in African children treated for falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
quantificationofglucose6phosphatedehydrogenaseactivitybyspectrophotometryasystematicreviewandmetaanalysis
‡A
Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
quantificationofplasmodiumexvivodrugsusceptibilitybyflowcytometry
‡A
Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry
‡9
1
|
|
919
|
|
|
‡a
quantifyingprimaquineeffectivenessandimprovingadherencearoundtablediscussionoftheapmenvivaxworkinggroup
‡A
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.
‡9
1
|
|
919
|
|
|
‡a
quinolone3diarylethersanewclassofantimalarialdrug
‡A
Quinolone-3-diarylethers: a new class of antimalarial drug.
‡9
1
|
|
919
|
|
|
‡a
rapidclinicalassessmenttofacilitatethetriageofadultswithfalciparummalariaaretrospectiveanalysis
‡A
Rapid clinical assessment to facilitate the triage of adults with falciparum malaria, a retrospective analysis
‡9
1
|
|
919
|
|
|
‡a
recoveryofendothelialfunctioninseverefalciparummalariarelationshipwithimprovementinplasma50arginineandbloodlactateconcentrations
‡A
Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations
‡9
1
|
|
919
|
|
|
‡a
relationshipofcellfreehemoglobintoimpairedendothelialnitricoxidebioavailabilityandperfusioninseverefalciparummalaria
‡A
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
reviewofkeyknowledgegapsinglucose6phosphatedehydrogenasedeficiencydetectionwithregardtothesafeclinicaldeploymentof8aminoquinolinetreatmentregimensaworkshopreport
‡A
Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report
‡9
1
|
|
919
|
|
|
‡a
riskofplasmodiumvivaxparasitaemiaafterplasmodiumfalciparuminfectionasystematicreviewandmetaanalysis
‡A
Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
safetyofprimaquineininfantswithplasmodiumvivaxmalariainpapuaindonesia
‡A
Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
safetyprofileof50arginineinfusioninmoderatelyseverefalciparummalaria
‡A
Safety profile of L-arginine infusion in moderately severe falciparum malaria
‡9
1
|
|
919
|
|
|
‡a
severecongenitalmalariaacquiredinutero
‡A
Severe congenital malaria acquired in utero
‡9
1
|
|
919
|
|
|
‡a
severemalarialthrombocytopeniaariskfactorformortalityinpapuaindonesia
‡A
Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
shortcourseprimaquinefortheradicalcureofplasmodiumvivaxmalariaamulticentrerandomisedplacebocontrollednoninferioritytrial
‡A
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial
‡9
1
|
|
919
|
|
|
‡a
singledoseradicalcureofplasmodiumvivaxastepcloser
‡A
Single-dose radical cure of Plasmodium vivax: a step closer
‡9
1
|
|
919
|
|
|
‡a
spectrophotometryassaystodetermineg6pdactivityfromtrinitybiotechandpointescientificg6pdshowgoodcorrelation
‡A
Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation
‡9
1
|
|
919
|
|
|
‡a
strongeractivityofhumanimmunodeficiencyvirustype1proteaseinhibitorsagainstclinicalisolatesofplasmodiumvivaxthanagainstthoseofpfalciparum
‡A
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
‡9
1
|
|
919
|
|
|
‡a
submicroscopicandasymptomaticplasmodiumparasitaemiaassociatedwithsignificantriskofanaemiainpapuaindonesia
‡A
Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia
‡9
1
|
|
919
|
|
|
‡a
tafenoquinefortheradicalcureandpreventionofmalariatheimportanceoftestingforg6pddeficiency
‡A
Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency
‡9
1
|
|
919
|
|
|
‡a
burdenandtreatmentofhivintuberculosispatientsinpapuaprovinceindonesiaaprospectiveobservationalstudy
‡A
The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study
‡9
1
|
|
919
|
|
|
‡a
challengesofintroducingroutineg6pdtestingintoradicalcureaworkshopreport
‡A
The challenges of introducing routine G6PD testing into radical cure: a workshop report
‡9
1
|
|
919
|
|
|
‡a
clinicalimplicationsofthrombocytopeniainadultswithseverefalciparummalariaaretrospectiveanalysis
‡A
The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis
‡9
1
|
|
919
|
|
|
‡a
effectofchloroquinedoseandprimaquineonplasmodiumvivaxrecurrenceaworldwideantimalarialresistancenetworksystematicreviewandindividualpatientpooledmetaanalysis
‡A
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
‡9
1
|
|
943
|
|
|
‡a
201x
‡A
2010
‡9
3
|
|
943
|
|
|
‡a
200x
‡A
2003
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
LC|no 98061838
|
|
996
|
|
|
‡2
BAV|495_105059
|
|
996
|
|
|
‡2
DNB|172546214
|
|
996
|
|
|
‡2
NUKAT|n 2006089824
|
|
996
|
|
|
‡2
ISNI|0000000044659289
|
|
996
|
|
|
‡2
JPG|500085780
|
|
996
|
|
|
‡2
CAOONL|ncf12090922
|
|
996
|
|
|
‡2
ISNI|0000000392143174
|
|
996
|
|
|
‡2
DBC|87097991883791
|
|
996
|
|
|
‡2
LIH|LNB:5X_m_;=B_g_
|
|
996
|
|
|
‡2
DNB|122610806
|
|
996
|
|
|
‡2
ISNI|0000000038994515
|
|
996
|
|
|
‡2
NLA|000035832219
|
|
996
|
|
|
‡2
BNF|14002191
|
|
996
|
|
|
‡2
BIBSYS|10071235
|
|
996
|
|
|
‡2
BNF|13594141
|
|
996
|
|
|
‡2
LC|n 2001038341
|
|
996
|
|
|
‡2
LC|no2004087532
|
|
996
|
|
|
‡2
CAOONL|ncf10371501
|
|
996
|
|
|
‡2
ISNI|0000000114510405
|
|
996
|
|
|
‡2
LC|n 2018007942
|
|
996
|
|
|
‡2
RERO|A003711744
|
|
996
|
|
|
‡2
RERO|A003711740
|
|
996
|
|
|
‡2
NTA|180647288
|
|
996
|
|
|
‡2
NUKAT|n 98031091
|
|
996
|
|
|
‡2
NTA|089616421
|
|
996
|
|
|
‡2
J9U|987007290376905171
|
|
996
|
|
|
‡2
NII|DA02277479
|
|
996
|
|
|
‡2
BIBSYS|90586751
|
|
996
|
|
|
‡2
DNB|116289813
|
|
996
|
|
|
‡2
NUKAT|n 2005097067
|
|
996
|
|
|
‡2
LC|n 2009057888
|
|
996
|
|
|
‡2
LC|no2009111481
|
|
996
|
|
|
‡2
NLA|000035433326
|
|
996
|
|
|
‡2
NLA|000035433321
|
|
996
|
|
|
‡2
BIBSYS|90333603
|
|
996
|
|
|
‡2
BIBSYS|90178658
|
|
996
|
|
|
‡2
KRNLK|KAC200508608
|
|
996
|
|
|
‡2
LC|no2004023126
|
|
996
|
|
|
‡2
LNB|LNC10-000005256
|
|
996
|
|
|
‡2
SUDOC|068737610
|
|
996
|
|
|
‡2
LC|no2014116244
|
|
996
|
|
|
‡2
J9U|987007605652805171
|
|
996
|
|
|
‡2
ISNI|0000000115072777
|
|
996
|
|
|
‡2
BIBSYS|8009535
|
|
996
|
|
|
‡2
CAOONL|ncf10195697
|
|
996
|
|
|
‡2
SELIBR|237087
|
|
996
|
|
|
‡2
BNF|12364152
|
|
996
|
|
|
‡2
BIBSYS|90072159
|
|
996
|
|
|
‡2
ISNI|0000000387581823
|
|
996
|
|
|
‡2
J9U|987007355874705171
|
|
996
|
|
|
‡2
NTA|146291409
|
|
996
|
|
|
‡2
LC|n 79006410
|
|
996
|
|
|
‡2
LC|nb 96067036
|
|
996
|
|
|
‡2
BNF|12055978
|
|
996
|
|
|
‡2
ISNI|0000000116108428
|
|
996
|
|
|
‡2
DBC|87097991883805
|
|
996
|
|
|
‡2
ISNI|0000000393971748
|
|
996
|
|
|
‡2
LC|n 86001118
|
|
996
|
|
|
‡2
LC|n 80062085
|
|
996
|
|
|
‡2
NTA|068457804
|
|
996
|
|
|
‡2
SUDOC|08589141X
|
|
996
|
|
|
‡2
NTA|228127459
|
|
996
|
|
|
‡2
N6I|vtls000328766
|
|
996
|
|
|
‡2
NII|DA08028794
|
|
996
|
|
|
‡2
SUDOC|243786972
|
|
996
|
|
|
‡2
RERO|A020065213
|
|
996
|
|
|
‡2
LNB|LNC10-000135248
|
|
996
|
|
|
‡2
DNB|1238801463
|
|
996
|
|
|
‡2
J9U|987007364380805171
|
|
996
|
|
|
‡2
SELIBR|317843
|
|
996
|
|
|
‡2
LC|n 88620341
|
|
996
|
|
|
‡2
NKC|xx0131677
|
|
996
|
|
|
‡2
ISNI|0000000081852571
|
|
996
|
|
|
‡2
NUKAT|n 2017028295
|
|
996
|
|
|
‡2
DNB|1089652313
|
|
996
|
|
|
‡2
LC|nr 93009158
|
|
996
|
|
|
‡2
NUKAT|n 2022132326
|
|
996
|
|
|
‡2
NII|DA04541534
|
|
996
|
|
|
‡2
J9U|987007425127705171
|
|
996
|
|
|
‡2
ISNI|0000000052939651
|
|
996
|
|
|
‡2
ISNI|0000000372711007
|
|
996
|
|
|
‡2
BNF|15127364
|
|
996
|
|
|
‡2
BNF|12480198
|
|
996
|
|
|
‡2
ISNI|0000000114481501
|
|
996
|
|
|
‡2
J9U|987007327969505171
|
|
996
|
|
|
‡2
NLA|000035818623
|
|
996
|
|
|
‡2
SZ|134160800
|
|
996
|
|
|
‡2
DNB|1056525193
|
|
996
|
|
|
‡2
NLA|000035433311
|
|
996
|
|
|
‡2
DNB|119229137
|
|
996
|
|
|
‡2
RERO|A003711731
|
|
996
|
|
|
‡2
RERO|A003711730
|
|
996
|
|
|
‡2
RERO|A003711732
|
|
996
|
|
|
‡2
NTA|176523405
|
|
996
|
|
|
‡2
BIBSYS|1031174
|
|
996
|
|
|
‡2
DNB|134160800
|
|
996
|
|
|
‡2
BIBSYS|13049684
|
|
996
|
|
|
‡2
NLA|000035946906
|
|
996
|
|
|
‡2
J9U|987007266764105171
|
|
996
|
|
|
‡2
NSK|000409952
|
|
996
|
|
|
‡2
CAOONL|ncf12061041
|
|
996
|
|
|
‡2
NDL|00453329
|
|
996
|
|
|
‡2
NTA|069994927
|
|
996
|
|
|
‡2
SUDOC|079028519
|
|
996
|
|
|
‡2
SUDOC|029667313
|
|
996
|
|
|
‡2
BNF|12281953
|
|
996
|
|
|
‡2
LC|n 2018046527
|
|
996
|
|
|
‡2
CAOONL|ncf10331459
|
|
996
|
|
|
‡2
LC|n 93803736
|
|
996
|
|
|
‡2
PLWABN|9811738962905606
|
|
996
|
|
|
‡2
BNE|XX1512793
|
|
996
|
|
|
‡2
CAOONL|ncf10245336
|
|
996
|
|
|
‡2
ISNI|0000000081761119
|
|
996
|
|
|
‡2
PLWABN|9810679982505606
|
|
996
|
|
|
‡2
ISNI|0000000029386737
|
|
996
|
|
|
‡2
LC|n 81103822
|
|
996
|
|
|
‡2
LIH|LNB:BRWI;=BQ
|
|
996
|
|
|
‡2
ISNI|0000000043165471
|
|
996
|
|
|
‡2
BNE|XX955758
|
|
996
|
|
|
‡2
LC|n 84102015
|
|
996
|
|
|
‡2
DNB|12969455X
|
|
996
|
|
|
‡2
LC|no 93006128
|
|
996
|
|
|
‡2
LC|no2008038281
|
|
996
|
|
|
‡2
CAOONL|ncf10047830
|
|
996
|
|
|
‡2
ISNI|0000000024907302
|
|
996
|
|
|
‡2
ISNI|0000000071059852
|
|
996
|
|
|
‡2
BAV|495_279848
|
|
996
|
|
|
‡2
NKC|jo20181001704
|
|
996
|
|
|
‡2
ISNI|000000011974477X
|
|
996
|
|
|
‡2
DNB|170084787
|
|
996
|
|
|
‡2
SUDOC|029519799
|
|
996
|
|
|
‡2
NII|DA02328241
|
|
996
|
|
|
‡2
DBC|87097919001458
|
|
996
|
|
|
‡2
B2Q|0000819291
|
|
996
|
|
|
‡2
NII|DA04803211
|
|
996
|
|
|
‡2
BNC|981058594343306706
|
|
996
|
|
|
‡2
BNF|14696056
|
|
996
|
|
|
‡2
VLACC|000031647
|
|
996
|
|
|
‡2
NKC|xx0100358
|
|
996
|
|
|
‡2
NTA|069357897
|
|
996
|
|
|
‡2
BIBSYS|1041888
|
|
996
|
|
|
‡2
SUDOC|268393877
|
|
996
|
|
|
‡2
SIMACOB|37770083
|
|
996
|
|
|
‡2
W2Z|90549773
|
|
996
|
|
|
‡2
ISNI|0000000109309600
|
|
996
|
|
|
‡2
RERO|A012350775
|
|
996
|
|
|
‡2
NTA|069554706
|
|
996
|
|
|
‡2
LC|no2017162328
|
|
996
|
|
|
‡2
SIMACOB|309130595
|
|
996
|
|
|
‡2
BNC|981061116162506706
|
|
996
|
|
|
‡2
ISNI|0000000082490939
|
|
996
|
|
|
‡2
CAOONL|ncf11223877
|
|
996
|
|
|
‡2
BIBSYS|90549773
|
|
996
|
|
|
‡2
SELIBR|346762
|
|
996
|
|
|
‡2
PTBNP|1933549
|
|
996
|
|
|
‡2
LC|no2017126538
|
|
996
|
|
|
‡2
ISNI|0000000054331762
|
|
996
|
|
|
‡2
LC|nb2010022173
|
|
996
|
|
|
‡2
SUDOC|075957450
|
|
996
|
|
|
‡2
LC|no2012004616
|
|
996
|
|
|
‡2
ISNI|0000000042321188
|
|
996
|
|
|
‡2
ISNI|0000000053626753
|
|
996
|
|
|
‡2
BIBSYS|90113012
|
|
996
|
|
|
‡2
NUKAT|n 02060583
|
|
996
|
|
|
‡2
BNF|15597432
|
|
996
|
|
|
‡2
ISNI|0000000080317446
|
|
996
|
|
|
‡2
NKC|kv2010540454
|
|
996
|
|
|
‡2
RERO|A012439433
|
|
996
|
|
|
‡2
BNF|12302528
|
|
996
|
|
|
‡2
NII|DA02360277
|
|
996
|
|
|
‡2
NUKAT|n 2009106979
|
|
996
|
|
|
‡2
ISNI|0000000068319051
|
|
996
|
|
|
‡2
ISNI|0000000451497248
|
|
996
|
|
|
‡2
BNE|XX969806
|
|
996
|
|
|
‡2
N6I|vtls001251417
|
|
996
|
|
|
‡2
NII|DA11128855
|
|
996
|
|
|
‡2
ISNI|0000000451696773
|
|
996
|
|
|
‡2
DBC|87097969654215
|
|
996
|
|
|
‡2
DNB|134773845
|
|
996
|
|
|
‡2
LC|nr 00038787
|
|
996
|
|
|
‡2
NKC|mub20211114191
|
|
996
|
|
|
‡2
BIBSYS|90578681
|
|
996
|
|
|
‡2
NTA|073481181
|
|
996
|
|
|
‡2
SUDOC|161892280
|
|
996
|
|
|
‡2
SIMACOB|237767267
|
|
996
|
|
|
‡2
SELIBR|387895
|
|
996
|
|
|
‡2
ISNI|0000000383706617
|
|
996
|
|
|
‡2
NLA|000035433303
|
|
996
|
|
|
‡2
BIBSYS|90843228
|
|
996
|
|
|
‡2
RERO|A011532819
|
|
996
|
|
|
‡2
LC|n 80156545
|
|
996
|
|
|
‡2
DNB|12261089X
|
|
996
|
|
|
‡2
BNF|12275808
|
|
996
|
|
|
‡2
LC|no 90003636
|
|
996
|
|
|
‡2
BNF|13523299
|
|
996
|
|
|
‡2
ISNI|0000000108794691
|
|
996
|
|
|
‡2
BNF|11920631
|
|
996
|
|
|
‡2
NUKAT|n 99051709
|
|
996
|
|
|
‡2
ISNI|0000000116137771
|
|
996
|
|
|
‡2
LC|n 81065951
|
|
996
|
|
|
‡2
LC|n 80021763
|
|
996
|
|
|
‡2
ISNI|0000000442964983
|
|
996
|
|
|
‡2
RERO|A012325610
|
|
996
|
|
|
‡2
NSK|000066660
|
|
996
|
|
|
‡2
B2Q|0000288006
|
|
996
|
|
|
‡2
NKC|vse2012676745
|
|
996
|
|
|
‡2
LC|n 94096118
|
|
996
|
|
|
‡2
NUKAT|n 2014010651
|
|
996
|
|
|
‡2
BIBSYS|90633869
|
|
996
|
|
|
‡2
DNB|1114745413
|
|
996
|
|
|
‡2
BIBSYS|1459181432270
|
|
996
|
|
|
‡2
ISNI|0000000114562432
|
|
996
|
|
|
‡2
NTA|068042078
|
|
996
|
|
|
‡2
LC|nr 88003534
|
|
996
|
|
|
‡2
BNF|12112997
|
|
996
|
|
|
‡2
J9U|987010326787305171
|
|
996
|
|
|
‡2
BIBSYS|90152639
|
|
996
|
|
|
‡2
ISNI|0000000108904256
|
|
996
|
|
|
‡2
CAOONL|ncf10271386
|
|
996
|
|
|
‡2
NUKAT|n 2008103968
|
|
996
|
|
|
‡2
LC|nr2003035660
|
|
996
|
|
|
‡2
RERO|A020051459
|
|
996
|
|
|
‡2
CAOONL|ncf10912911
|
|
996
|
|
|
‡2
CAOONL|ncf10912910
|
|
996
|
|
|
‡2
LC|n 80011246
|
|
996
|
|
|
‡2
LIH|LNB:BF9_z_;=B_h_
|
|
996
|
|
|
‡2
PLWABN|9810557275605606
|
|
996
|
|
|
‡2
PLWABN|9810560246805606
|
|
996
|
|
|
‡2
ISNI|0000000041144888
|
|
996
|
|
|
‡2
KRNLK|KAC200603105
|
|
996
|
|
|
‡2
ISNI|000000000207993X
|
|
996
|
|
|
‡2
LC|no2009171037
|
|
996
|
|
|
‡2
NII|DA00377086
|
|
996
|
|
|
‡2
CAOONL|ncf11250964
|
|
996
|
|
|
‡2
LC|n 79078647
|
|
996
|
|
|
‡2
ISNI|0000000500515765
|
|
996
|
|
|
‡2
ISNI|0000000023614348
|
|
996
|
|
|
‡2
CAOONL|ncf10230755
|
|
996
|
|
|
‡2
LC|n 80135788
|
|
996
|
|
|
‡2
N6I|vtls002581159
|
|
996
|
|
|
‡2
ISNI|0000000387385785
|
|
996
|
|
|
‡2
J9U|987007355678605171
|
|
996
|
|
|
‡2
BIBSYS|90596292
|
|
996
|
|
|
‡2
J9U|987007341916205171
|
|
996
|
|
|
‡2
BLBNB|000558272
|
|
996
|
|
|
‡2
LC|n 00078301
|
|
996
|
|
|
‡2
SUDOC|103121242
|
|
996
|
|
|
‡2
BNF|12442493
|
|
996
|
|
|
‡2
ISNI|0000000044308104
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
|
998
|
|
|
‡a
Price, Ric
‡2
LC|no2013074810
‡3
suggested
‡3
title: (0.91, 'epidemiologyofplasmodiumvivax', 'epidemiologyofplasmodiumvivaxpreface')
|
|
998
|
|
|
‡a
Price, Richard
‡2
ISNI|0000000116137771
‡3
exact name
|
|
998
|
|
|
‡a
Richard Price
‡2
ISNI|0000000116137771
‡3
exact name
|
|
998
|
|
|
‡a
Price, Richard
‡2
ISNI|0000000116137771
‡3
exact name
|
|
998
|
|
|
‡a
Price, Richard
‡2
ISNI|0000000116137771
‡3
exact name
|
|
998
|
|
|
‡a
Price, Ric
‡2
BIBSYS|13010493
‡3
suggested
‡3
viafid
‡3
title: (0.71, 'epidemiologyofplasmodiumvivaxhistoryhiatusandhubris', 'epidemiologyofplasmodiumvivaxpreface')
|
